Jason Kolbert


Maxim Keeps ‘Buy’ On Agenus Following Phase 2 Trial Data From HerpV

In a research note issued today, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Agenus Inc. (AGEN) and a price target of $11, after AGEN announced the final data set …

Maxim Keeps ‘Buy’ On Vertex Pharmaceuticals, Raises Price Target To $107

In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on Vertex Pharmaceuticals (VRTX) and increased his price target to $107.00 (from $92.

Maxim Keeps ‘Buy’ On Stem Cells Following Interim Phase I/II Trial Data

In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on StemCells Inc. (STEM), and a price target of $2.

Maxim Reiterates ‘Buy’ On Inovio Pharmaceuticals, Adjusts Price Target

In a report published today, Maxim analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals, Inc. (INO) with an adjusted price target of $18.

Maxim Reiterates Buy Rating And Raises Achillion Price Target To $22

In a research note issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating and boosted his price target on Achillion Pharmaceuticals (ACHN) to …

Maxim Group Assumes Advanced Cell Technology at Buy

In a research note released today, Maxim Group assumed coverage on Advanced Cell Technology, Inc. (ACTC) with a Buy rating and a price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts